Insulet Co. (NASDAQ:PODD) Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp reduced its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 177,338 shares of the medical instruments supplier’s stock after selling 3,405 shares during the quarter. Insulet comprises 2.5% of AMI Asset Management Corp’s portfolio, making the stock its 17th biggest holding. AMI Asset Management Corp’s holdings in Insulet were worth $46,298,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in PODD. Marshall Wace LLP acquired a new position in shares of Insulet during the 2nd quarter worth $99,978,000. Baillie Gifford & Co. increased its holdings in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Mizuho Securities USA LLC raised its position in Insulet by 5,928.1% during the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after acquiring an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Insulet by 43.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares during the last quarter.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $275.81 on Tuesday. The firm has a market capitalization of $19.35 billion, a PE ratio of 47.23, a P/E/G ratio of 3.46 and a beta of 1.22. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50-day moving average of $266.30 and a two-hundred day moving average of $233.51.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

PODD has been the topic of a number of recent research reports. Citigroup upped their target price on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein began coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. BTIG Research lifted their price target on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Barclays upped their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Finally, TD Cowen lifted their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.